NewAmsterdam Reports $17.4 Million Quarterly Loss as Drug Advances
The company reported higher quarterly revenue, European approvals for two obicetrapib products and plans for key trial updates.
Makkler Newsroom · Nov 4, 08:52 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $51.73 (+165.8%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.